Marylyn Addo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8539350/publications.pdf

Version: 2024-02-01

137 papers	13,636 citations	36303 51 h-index	22166 113 g-index
147 all docs	147 docs citations	147 times ranked	18804 citing authors

#	Article	IF	Citations
1	Predictors of somatic symptom burden in healthcare professionals during the COVID-19 pandemic: an 8-week follow-up study. Journal of Mental Health, 2023, 32, 1111-1121.	1.9	4
2	SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Clinical Gastroenterology and Hepatology, 2022, 20, 162-172.e9.	4.4	113
3	T cells expressing multiple coâ€inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice. European Journal of Immunology, 2022, 52, 312-327.	2.9	8
4	Attitudes, practices, and obstacles towards influenza vaccination for international travelers among travel health advisors in Germany: A questionnaire-based survey. Travel Medicine and Infectious Disease, 2022, 45, 102233.	3.0	0
5	Molecular consequences of SARS-CoV-2 liver tropism. Nature Metabolism, 2022, 4, 310-319.	11.9	98
6	SARSâ€CoVâ€2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterology Journal, 2022, 10, 319-329.	3.8	27
7	Lack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General. Pathogens, 2022, 11, 18.	2.8	4
8	SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia, 2022, 36, 562-565.	7.2	23
9	Respiratory muscle dysfunction in long-COVID patients. Infection, 2022, 50, 1391-1397.	4.7	14
10	High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19. Viruses, 2022, 14, 1265.	3.3	5
11	Three Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 Infection Elicit Strong Humoral Immune Responses in Healthcare Workers. Vaccines, 2022, 10, 1086.	4.4	3
12	Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cellâ€“Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2021, 73, e4020-e4024.	5.8	47
13	Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and metaâ€analysis. Liver International, 2021, 41, 449-455.	3.9	16
14	Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study. International Journal of Hygiene and Environmental Health, 2021, 232, 113671.	4.3	37
15	B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19. Journal of Leukocyte Biology, 2021, 109, 77-90.	3.3	46
16	Extensive Antibiotic and Antimalarial Prescription Rate among Children with Acute Febrile Diseases in the Lake Victoria Region, Tanzania. Journal of Tropical Pediatrics, 2021, 67, .	1.5	5
17	Less than youâ€™d thinkâ€”a prospective study on MRSA-colonization in healthy travellers. Journal of Travel Medicine, 2021, 28, .	3.0	2
18	The COVID-19 Vaccine Landscape. Advances in Experimental Medicine and Biology, 2021, 1318, 549-573.	1.6	9

#	Article	IF	Citations
19	Clonal expansion and activation of tissue-resident memory-like T _H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. Science Immunology, 2021, 6, .	11.9	125
20	Multiplex-RT-PCR-ELISA panel for detecting mosquito-borne pathogens: Plasmodium sp. preserved and eluted from dried blood spots on sample cards. Malaria Journal, 2021, 20, 66.	2.3	5
21	Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study. Frontiers in Neurology, 2021, 12, 632535.	2.4	12
22	Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Scientific Reports, 2021, 11, 5803.	3.3	40
23	Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines, 2021, 9, 238.	4.4	49
24	Malaria in the Time of COVID-19: Do Not Miss the Real Cause of Illness. Tropical Medicine and Infectious Disease, 2021, 6, 40.	2.3	6
25	Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series. Pathogens, 2021, 10, 438.	2.8	21
26	SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies. Viruses, 2021, 13, 661.	3.3	27
27	A simple, sensitive, and lowâ€cost FACS assay for detecting antibodies against the native SARSâ€CoVâ€2 spike protein. Immunity, Inflammation and Disease, 2021, 9, 905-917.	2.7	5
28	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. International Journal of Infectious Diseases, 2021, 106, 265-268.	3.3	1
29	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. Journal of Clinical Medicine, 2021, 10, 2274.	2.4	19
30	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	4.1	9
31	Scent dog identification of SARS-CoV-2 infections in different body fluids. BMC Infectious Diseases, 2021, 21, 707.	2.9	24
32	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. Journal of Clinical Medicine, 2021, 10, 3049.	2.4	12
33	Hepatitis E virus persists in the ejaculate of chronically infected men. Journal of Hepatology, 2021, 75, 55-63.	3.7	17
34	Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. International Journal of Hygiene and Environmental Health, 2021, 238, 113851.	4.3	13
35	Risk factors for and management of metronidazole-refractory giardiasis in international travellers: A retrospective analysis. Travel Medicine and Infectious Disease, 2021, 43, 102090.	3.0	7
36	Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues. Molecular Therapy - Methods and Clinical Development, 2021, 23, 418-423.	4.1	5

#	Article	IF	Citations
37	Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial. Vaccines, 2021, 9, 1208.	4.4	2
38	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Frontiers in Medicine, 2021, 8, 749588.	2.6	17
39	Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19. Frontiers in Immunology, 2021, 12, 798276.	4.8	3
40	TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasisâ€“A case series and review of the literature. PLoS Neglected Tropical Diseases, 2021, 15, e0010065.	3.0	7
41	No link between male infertility and HEV genotype 3 infection. Gut, 2020, 69, 1150-1151.	12.1	12
42	Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. Journal of Clinical Virology, 2020, 130, 104549.	3.1	54
43	Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Annals of Internal Medicine, 2020, 173, 268-277.	3.9	1,954
44	Scent dog identification of samples from COVID-19 patients â€“ a pilot study. BMC Infectious Diseases, 2020, 20, 536.	2.9	132
45	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. Pathogens, 2020, 9, 755.	2.8	7
46	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. Viruses, 2020, 12, 915.	3.3	13
47	Integration of microarray data and literature mining identifies a sex bias in DPP4+CD4+ T cells in HIV-1 infection. PLoS ONE, 2020, 15, e0239399.	2.5	4
48	Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101). Biomolecules, 2020, 10, 1171.	4.0	21
49	Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals. Journal of Hepatology, 2020, 73, S858.	3.7	1
50	Risk factors for different intestinal pathogens among patients with traveler's diarrhea: A retrospective analysis at a German travel clinic (2009â€“2017). Travel Medicine and Infectious Disease, 2020, 37, 101706.	3.0	6
51	Epitopes of Naturally Acquired and Vaccineâ€Induced Antiâ€Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. Biotechnology Journal, 2020, 15, 2000069.	3.5	9
52	Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV. Vaccines, 2020, 8, 142.	4.4	3
53	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity, 2020, 53, 442-455.e4.	14.3	281
54	Relapsing cutaneous leishmaniasis in a patient requiring TNF-Î±-inhibitor Infliximab for Takayasu-arteritis: Case report and review of the literature. Travel Medicine and Infectious Disease, 2020, 37, 101700.	3.0	2

#	Article	IF	Citations
55	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 827-838.	9.1	125
56	Integrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells. Frontiers in Immunology, 2020, 11, 607889.	4.8	1
57	Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens. Frontiers in Immunology, 2020, 11, 601170.	4.8	33
58	Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Communications, 2020, 2, fcaa205.	3.3	236
59	Seroconversion of HBsAG coincides super-infection with hepatitis A: A case report. World Journal of Clinical Cases, 2020, 8, 1651-1655.	0.8	4
60	Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Human Vaccines and Immunotherapeutics, 2019, 15, 2269-2285.	3.3	58
61	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine, 2019, 25, 1589-1600.	30.7	92
62	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Research and Therapy, 2019, 16, 34.	1.7	16
63	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. Travel Medicine and Infectious Disease, 2019, 30, 130-132.	3.0	9
64	Brain magnetic resonance imaging in imported malaria. Malaria Journal, 2019, 18, 74.	2.3	8
65	Determinants of post-malarial anemia in African children treated with parenteral artesunate. Scientific Reports, 2019, 9, 18134.	3.3	6
66	Detectable Vesicular Stomatitis Virus (VSV)â€“Specific Humoral and Cellular Immune Responses Following VSVâ€“Ebola Virus Vaccination in Humans. Journal of Infectious Diseases, 2019, 219, 556-561.	4.0	29
67	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 738-748.	9.1	62
68	Differential expression pattern of co-inhibitory molecules on CD4+ T cells in uncomplicated versus complicated malaria. Scientific Reports, 2018, 8, 4789.	3.3	31
69	HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. Journal of Hepatology, 2018, 69, 36-42.	3.7	80
70	Epidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center. Infection, 2018, 46, 847-853.	4.7	8
71	Comprehensive characterization of cellular immune responses following Ebola virus infection. Journal of Infectious Diseases, 2017, 215, jiw508.	4.0	38
72	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine, 2017, 19, 107-118.	6.1	64

#	Article	IF	Citations
73	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	6.4	107
74	Helminthic infections in returning travelers and migrants with eosinophilia: Diagnostic value of medical history, eosinophil count and IgE. Travel Medicine and Infectious Disease, 2017, 20, 49-55.	3.0	21
75	Pre-travel advice at a crossroad: Medical preparedness of travellers to South and Southeast-Asia - The Hamburg Airport Survey. Travel Medicine and Infectious Disease, 2017, 18, 41-45.	3.0	19
76	Acute HIV-1 infection is associated with increased plasma levels of heme oxygenase-1 and presence of heme oxygenase-1-specific regulatory T cells. Aids, 2017, 31, 635-641.	2.2	4
77	Response to fever and utilization of standby emergency treatment (SBET) for malaria in travellers to Southeast Asia: a questionnaire-based cohort study. Malaria Journal, 2017, 16, 44.	2.3	22
78	Molecular Diagnosis of Human Taenia martis Eye Infection. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1055-1057.	1.4	9
79	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	27.8	170
80	Rapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi. Open Forum Infectious Diseases, 2016, 3, ofw039.	0.9	11
81	Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study. Journal of Psychosomatic Research, 2016, 83, 69-74.	2.6	39
82	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New England Journal of Medicine, 2016, 374, 1647-1660.	27.0	355
83	Timâ€ blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients. Journal of the International AIDS Society, 2015, 18, 20078.	3.0	33
84	Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells. PLoS ONE, 2015, 10, e0118803.	2.5	47
85	Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia. New England Journal of Medicine, 2015, 372, 1376-1377.	27.0	15
86	Ebola and Psychological Stress of Health Care Professionals. Emerging Infectious Diseases, 2015, 21, 913-914.	4.3	95
87	HIV-1 Infection Impairs Regulatory T-Cell Suppressive Capacity on a Per-Cell Basis. Journal of Infectious Diseases, 2014, 210, 899-903.	4.0	24
88	A Dead-End Host: Is There a Way Out? A Position Piece on the Ebola Virus Outbreak by the International Union of Immunology Societies. Frontiers in Immunology, 2014, 5, 562.	4.8	1
89	A Case of Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia. New England Journal of Medicine, 2014, 371, 2394-2401.	27.0	270
90	Sex-Based Differences in HIV Type 1 Pathogenesis. Journal of Infectious Diseases, 2014, 209, S86-S92.	4.0	128

#	Article	IF	Citations
91	Regulatory T Cells Expanded from HIV-1-Infected Individuals Maintain Phenotype, TCR Repertoire and Suppressive Capacity. PLoS ONE, 2014, 9, e86920.	2.5	7
92	CD4 ⁺ CD25 ⁺ Regulatory T Cells Impair HIV-1-Specific CD4 T Cell Responses by Upregulating Interleukin-10 Production in Monocytes. Journal of Virology, 2012, 86, 6586-6594.	3.4	34
93	Regulatory T Cell Frequencies Do Not Correlate with Breadth or Magnitude of HIV-1-Specific T Cell Responses. AIDS Research and Human Retroviruses, 2012, 28, 749-751.	1.1	3
94	Bat3 promotes T cell responses and autoimmunity by repressing Tim-3â€“mediated cell death and exhaustion. Nature Medicine, 2012, 18, 1394-1400.	30.7	303
95	Lack of Detectable HIV-1â€“Specific CD8+ T Cell Responses in Zambian HIV-1â€“Exposed Seronegative Partners of HIV-1â€“Positive Individuals. Journal of Infectious Diseases, 2011, 203, 258-262.	4.0	18
96	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	12.6	1,054
97	Human Immunodeficiency Virus Type 1-Specific CD8⁺T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4⁺T Cells. Journal of Virology, 2009, 83, 7641-7648.	3.4	173
98	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
99	Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes. Journal of Virology, 2008, 82, 8422-8430.	3.4	114
100	Control of Human Immunodeficiency Virus Type 1 Is Associated with HLA-B*13 and Targeting of Multiple Gag-Specific CD8 + T-Cell Epitopes. Journal of Virology, 2007, 81, 3667-3672.	3.4	138
101	Fully Differentiated HIV-1 Specific CD8+ T Effector Cells Are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection. PLoS ONE, 2007, 2, e321.	2.5	89
102	Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire. Blood, 2006, 107, 2373-2383.	1.4	51
103	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178.	14.5	209
104	GB Virus C (GBVâ€C) Infection in Hepatitis C Virus (HCV)/HIVâ€“Coinfected Patients Receiving HCV Treatment: Importance of the GBVâ€C Genotype. Journal of Infectious Diseases, 2006, 194, 410-419.	4.0	56
105	The magnitude and breadth of hepatitis C virusâ€“specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood, 2005, 105, 1170-1178.	1.4	110
106	The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design. Journal of Virology, 2005, 79, 5000-5005.	3.4	39
107	Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. Journal of Immunology, 2005, 174, 7179-7185.	0.8	322
108	Differential Immunogenicity of HIVâ€1 Clade C Proteins in Eliciting CD8+and CD4+Cell Responses. Journal of Infectious Diseases, 2005, 192, 1588-1596.	4.0	51

#	Article	IF	Citations
109	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. Journal of Experimental Medicine, 2004, 199, 905-915.	8.5	266
110	Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. Journal of Virology, 2004, 78, 4463-4477.	3.4	171
111	Beyond Help: Direct Effector Functions of Human Immunodeficiency Virus Type 1-Specific CD4 + T Cells. Journal of Virology, 2004, 78, 8844-8851.	3.4	89
112	Loss of HIV-1â€“specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1â€“specific CD4+ T Cells. Journal of Experimental Medicine, 2004, 200, 701-712.	8.5	314
113	Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Medicine, 2004, 1, e36.	8.4	149
114	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature, 2004, 432, 769-775.	27.8	784
115	Differences in the Expressed HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses in Infected Chinese and Caucasians. AIDS Research and Human Retroviruses, 2004, 20, 557-564.	1.1	14
116	HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet, The, 2004, 363, 863-866.	13.7	100
117	HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids, 2004, 18, 1383-1392.	2.2	99
118	Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. Journal of Immunological Methods, 2003, 275, 19-29.	1.4	129
119	Rev Activity Determines Sensitivity of HIV-1-Infected Primary T Cells to CTL Killing. Immunity, 2003, 18, 289-299.	14.3	40
120	Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences. Journal of Virology, 2003, 77, 7330-7340.	3.4	133
121	HIV-1 Antiviral Activity of Recombinant Natural Killer Cell Enhancing Factors, NKEF-A and NKEF-B, Members of the Peroxiredoxin Family. Journal of Biological Chemistry, 2003, 278, 1569-1574.	3.4	87
122	Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids, 2003, 17, 2581-2591.	2.2	309
123	Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. Aids, 2003, 17, 1121-1126.	2.2	49
124	Consistent Patterns in the Development and Immunodominance of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 + T-Cell Responses following Acute HIV-1 Infection. Journal of Virology, 2002, 76, 8690-8701.	3.4	123
125	Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. Aids, 2002, 16, 321-328.	2.2	25
126	Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation. Journal of Virology, 2002, 76, 8757-8768.	3.4	241

#	Article	IF	Citations
127	HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection. Aids, 2002, 16, 1071-1073.	2.2	18
128	Evolution and transmission of stable CTL escape mutations in HIV infection. Nature, 2001, 412, 334-338.	27.8	523
129	Rapid Definition of Five Novel HLA-Aâˆ—3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays. Journal of Virology, 2001, 75, 1339-1347.	3.4	86
130	Vpr Is Preferentially Targeted by CTL During HIV-1 Infection. Journal of Immunology, 2001, 167, 2743-2752.	0.8	102
131	Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. Journal of Experimental Medicine, 2001, 193, 169-180.	8.5	363
132	Identification of Novel HLA-A2-Restricted Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Epitopes Predicted by the HLA-A2 Supertype Peptide-Binding Motif. Journal of Virology, 2001, 75, 1301-1311.	3.4	97
133	Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection. Journal of Experimental Medicine, 2001, 193, 181-194.	8.5	249
134	Identification of Dominant Optimal HLA-B60- and HLA-B61-Restricted Cytotoxic T-Lymphocyte (CTL) Epitopes: Rapid Characterization of CTL Responses by Enzyme-Linked Immunospot Assay. Journal of Virology, 2000, 74, 8541-8549.	3.4	99
135	Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. Journal of Hepatology, 1998, 29, 306-309.	3.7	112
136	Transmission of oral Candida albicans strains between HIV-positive patients. Lancet, The, 1995, 345, 1052-1053.	13.7	12
137	Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for SARSâ€CoVâ€2 delta and omicron variants. Journal of Medical Virology, 0, , .	5.0	6